Medicare Enrolled

Dr. Shelly Reardon, MD

Neurology with Special Qualifications in Child Neurology Physician · Austin, TX
5301 DAVIS LN BLDG A200, Austin, TX 78749
5124944000
Registered in NPPES since 2006
NPI: 1053363366 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Reardon from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reardon? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Reardon

Dr. Shelly Reardon is a neurology with special qualifications in child neurology physician in Austin, TX, with 20 years of NPI registration.

Between the years covered by Open Payments, Dr. Reardon received a total of $16,384 from 66 pharmaceutical and/or device companies across 527 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Reardon is High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration $16,384 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$16,384
Total received (2018-2024)
Avg $2,341/year across 7 years
Top 9% in TX for neurology with special qualifications in child neurology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
66
Companies
527
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,051
2023
$4,601
2022
$1,390
2021
$847
2020
$410
2019
$5,611
2018
$1,475

Payments by company (2024)

UCB, Inc.
$393
SK Life Science, Inc.
$246
Tris Pharma Inc
$159
IRONSHORE PHARMACEUTICALS INC.
$144
Corium, LLC
$110
Octapharma USA, Inc.
$100
Vertical Pharmaceuticals, LLC
$99
ACADIA Pharmaceuticals Inc
$95
Supernus Pharmaceuticals, Inc.
$76
Otter Pharmaceuticals, LLC
$75
CATALYST PHARMACEUTICALS, INC.
$67
Marinus Pharmaceuticals, Inc.
$59
JAZZ PHARMACEUTICALS INC.
$50
Amgen Inc.
$43
UPSHER-SMITH LABORATORIES LLC
$40
Neos Therapeutics, LP
$35
Avion Pharmaceuticals
$33
Mallinckrodt Hospital Products Inc.
$30
Pyros Pharmaceuticals, Inc.
$30
Kyowa Kirin, Inc.
$27
Pharming Healthcare, Inc.
$23
AQUESTIVE THERAPEUTICS, INC.
$23
NEUROPACE, INC.
$23
Medinc of Texas
$19
Baylis Medical Technologies Inc.
$18
Neurelis, Inc.
$18
Sumitomo Pharma America, Inc.
$14
Aucta Pharmaceuticals, Inc.
$3
Top 3 companies account for 38.9% of 2024 payments
All-time payments by company (2018-2024) ›
Admedus Corporation
$4,000
Abbott Laboratories
$2,649
UCB, Inc.
$1,293
Sunovion Pharmaceuticals Inc.
$1,031
Supernus Pharmaceuticals, Inc.
$824
Tris Pharma Inc
$567
SK Life Science, Inc.
$562
Amgen Inc.
$500
JAZZ PHARMACEUTICALS INC.
$316
Takeda Pharmaceuticals U.S.A., Inc.
$310
Corium, LLC
$278
Greenwich Biosciences, Inc.
$239
W. L. Gore & Associates, Inc.
$217
AQUESTIVE THERAPEUTICS, INC.
$216
ACADIA Pharmaceuticals Inc
$204
Shire North American Group Inc
$193
Neos Therapeutics, LP
$191
Medtronic Vascular, Inc.
$170
Octapharma USA, Inc.
$155
Sumitomo Pharma America, Inc.
$155
IRONSHORE PHARMACEUTICALS INC.
$144
Ironshore Pharmaceuticals Inc.
$142
Biogen, Inc.
$131
Vertical Pharmaceuticals, LLC
$123
Ipsen Biopharmaceuticals, Inc
$123
UPSHER-SMITH LABORATORIES LLC
$116
EISAI INC.
$108
PTC Therapeutics, Inc.
$77
Otter Pharmaceuticals, LLC
$75
Avion Pharmaceuticals
$67
CATALYST PHARMACEUTICALS, INC.
$67
GENZYME CORPORATION
$63
Neurelis, Inc.
$61
Marinus Pharmaceuticals, Inc.
$59
Lundbeck LLC
$57
Mallinckrodt LLC
$55
Eisai Inc.
$51
Upsher-Smith Laboratories LLC
$50
Zogenix Inc.
$48
Mallinckrodt Hospital Products Inc.
$45
Amneal Pharmaceuticals LLC
$41
LivaNova USA, Inc.
$40
ARBOR PHARMACEUTICALS, INC.
$40
Corium, Inc.
$39
Genentech USA, Inc.
$33
Arbor Pharmaceuticals, Inc.
$32
Pyros Pharmaceuticals, Inc.
$30
Jazz Pharmaceuticals Inc.
$28
Biocodex, Inc.
$28
Biohaven Pharmaceuticals, Inc.
$27
Kyowa Kirin, Inc.
$27
Novartis Pharmaceuticals Corporation
$25
TerSera Therapeutics LLC
$25
Janssen Biotech, Inc.
$24
Medtronic, Inc.
$24
Pharming Healthcare, Inc.
$23
NEUROPACE, INC.
$23
Saol Therapeutics Inc.
$21
Novartis Gene Therapies, Inc. (fka AveXis, Inc.)
$21
Medinc of Texas
$19
Ultragenyx Pharmaceutical Inc.
$18
Baylis Medical Technologies Inc.
$18
Antares Pharma, Inc.
$16
Sarepta Therapeutics, Inc.
$14
BioMarin Pharmaceutical Inc.
$12
Aucta Pharmaceuticals, Inc.
$3
Top 3 companies account for 48.5% of all-time payments
Associated products mentioned in payments ›
3F · ACTHAR · AFINITOR · APTIOM · AZSTARYS · Adzenys XR-ODT · Azstarys · Briviact · CRYSVITA · Cotempla XR-ODT · Crysvita · DAYBUE · DIACOMIT · DYSPORT · Dyanavel XR · Dysport · EMFLAZA · EPIDIOLEX · Edarbi · Emflaza · Enbrel · Epidiolex · Eprontia · Evekeo · Evrysdi · FYCOMPA · Fintepla · Fycompa · Horizant · JORNAY PM · Jornay PM 20mg capsules (Bottle of 100) · LIBERVANT · Lioresal Intrathecal (baclofen injection) · METHYLPHENIDATE 72 · MYDAYIS · Methylphenidate Hydrochloride · Mitra Clip system · Motpoly XR · NURTEC ODT · Nayzilam · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONFI · OTREXUP · OXTELLAR XR · PANZYGA · POMPE - DISEASE · Product in Development · QELBREE · QUDEXY XR Topiramate Extended Release Capsules · Qelbree · Quzyttir · RNS Neurostimulator Kit · RUCONEST · Relexxii · SPINRAZA · SYMPAZAN · SYNCHROMEDII · TORPENZ · TREMFYA · TROKENDI XR · VALTOCO · VIGADRONE · VIGADRONE (vigabatrin) for Oral Solution · VIGPODER · VNS Therapy · VYVANSE · Vimizim · Vyvanse · XYREM · Xyrem · ZOLGENSMA · ZOMIG · ZTALMY
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a neurology with special qualifications in child neurology physician in Austin?
Compare neurology with special qualifications in child neurology physicians in the Austin area by procedure volume, costs, and industry payment transparency.
Browse neurology with special qualifications in child neurology physicians nearby

Geographic Context

Neurology with special qualifications in child neurology physicians in nearby ZIP areas
21
County median income
$97,169
Nearest hospital to ZIP centroid (approximate)
AUSTIN OAKS HOSPITAL
3.5 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data — No data N/A
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Reardon is a neurology with special qualifications in child neurology physician, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Does Dr. Reardon receive payments from pharmaceutical companies?
Yes. Dr. Reardon received a total of $16,384 from 66 companies across 527 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Reardon) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →